Navigation Links
GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
Date:1/30/2009

lated to infusion reactions and infections. AEs seen in at least 10 percent of patients included fever, cough, diarrhea, rash, low white blood cell counts, fatigue, pneumonia, anemia, shortness of breath and nausea. In clinical trials to date, infusion reactions that were serious yet manageable were seen in three percent of patients. One case of progressive multifocal leukoencephalopathy (PML), a rare brain infection resulting in death or causing severe disability, and one case of tumor lysis syndrome were reported.(5,6) These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH) in December 2008.

Potential to Combat CLL in Earlier Stages

The companies also announced today the initiation of an additional Phase III study of ofatumumab in combination with fludarabine and cyclophosphamide (FC) for patients with CLL when initial treatment no longer works (second-line treatment). The open-label study will randomize 352 patients to evaluate progression-free survival (PFS) of ofatumumab in combination with FC therapy versus FC therapy alone for the treatment of relapsed CLL.(7) Enrollment for this study will begin shortly.

"Bolstered by the positive results of ofatumumab for advanced stage CLL, we're now investigating ofatumumab in earlier stages in the treatment continuum," said Paolo Paoletti, M.D., Senior Vice President of Oncology R&D, GSK. "The clues we're seeing from ofatumumab also suggest possible activity in other oncology settings, which we're currently evaluating through several clinical trials."

GSK and Genmab will conduct additional studies of ofatumumab in CLL and non-Hodgkin's lymphoma (NHL) settings. In CLL, a Phase III front-line study is evaluating ofatumumab combined with chlorambucil in patients with previously untreated CLL. In NHL, an ongoing Phase II study will assess ofatumumab in patients with Waldenstrom's Macroglobulinemia - a rare type of
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
2. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
3. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
4. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
5. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
6. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
7. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!
8. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
9. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
10. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
11. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2013)... CA (PRWEB) May 26, 2013 In the ... industry in China has been growing at an average ... growing steadily due to rises in poultry prices as well ... important in people's diets as a healthier alternative to other ... consumed in China, much lower than the world average. And ...
(Date:5/25/2013)... City, Utah (PRWEB) May 25, 2013 ... health insurance marketplaces . Zane Benefits, which provides ... benefits, is the leader in defined contribution plans ... Benefits’ website, the October 1, 2013 open enrollment of ... The mantra of the Marketplaces is "Choice, Competition and ...
(Date:5/25/2013)... 2013 Imagine running the air conditioner with ... hot air and wasted energy! If the home has a ... or clothes dryer, that may be just what is occurring ... overlooked holes waste energy in the form of higher energy ... loss in the home. , Drafts occur through the small ...
(Date:5/25/2013)... 25, 2013 Dr. Leslie Gerstman ... FDA-approved to lift skin on the neck, on the brow ... practice, Medical Aesthetics. , Ultherapy is a non-surgical procedure for ... healing process to lift the skin over time. The use ... to see and then treat the deepest support layers of ...
(Date:5/25/2013)... FL (PRWEB) May 25, 2013 Communities ... Worth, Texas. It is the fifth largest media market in ... is the number one visitor destination in Texas and a ... gateway to the American West as it is home to ... everyone will enjoy from sports to the arts. Residents and ...
Breaking Medicine News(10 mins):Health News:Poultry Farming Industry in China Industry Research Report – Now Available from IBISWorld 2Health News:Poultry Farming Industry in China Industry Research Report – Now Available from IBISWorld 3Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 2Health News:Zane Benefits Publishes New Information on the Health Insurance Marketplaces 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2
... WASHINGTON, DC, December 13, 2011 An Indiana University ... found that these men have unique ways of managing ... This ability, which Dr. Christian A. Vaccaro and colleagues ... for managing emotion and a means for conveying a ...
... with Parkinson,s disease swing their arms asymmetrically -- one ... This unusual movement is easily detected early when drugs ... to Penn State researchers who used inexpensive accelerometers on ... swing. "Scientists have known for some time that ...
... SAN DIEGO - A large-scale analysis of patients whose ... the notion that all of them have a poor ... Cancer Center report at the 53rd Annual Meeting of ... disease springs from earlier radiation, chemotherapy or both treatments ...
... a bed has to deal with numerous complications. Frequently, ... call them. Bony prominences, such as the sacrum, coccyx ... lead to tissue necrosis. Damage can extend into the ... ulcers are entryways for germs, which can trigger sepsis. ...
... Undiagnosed chronic fatigue syndrome may account for up to 1 ... periods of time and are not truant or known to ... school, a new study reveals. For the study, researchers ... three secondary schools in England and concluded that undiagnosed chronic ...
... problems of archaic logistics infrastructure, inefficient distribution channels and ... Africa is to cope with the growing problem of ... International Journal of Logistics Systems and Management . ... has been eradicated in some regions it remains the ...
Cached Medicine News:Health News:Study explores men's ability to manage fear in ways that allow them to exhibit confidence 2Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 2Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 3Health News:Prognostic model developed for MDS related to prior cancer therapy 2Health News:Prognostic model developed for MDS related to prior cancer therapy 3Health News:Lying and sitting more comfortably 2Health News:Chronic Fatigue Tied to Extended School Absences 2Health News:A logistics approach to malaria in Africa 2
(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...
(Date:5/24/2013)... , May 24, 2013 The ... for systemic delivery of therapeutic agents has been receiving ... drug delivery showing significant promise. The crucial formulation considerations ... delivery device play a major role in the efficiency ... in the development of new formulation techniques and devices ...
(Date:5/23/2013)... May 24, 2013 3SBio Inc. (NASDAQ: ... a leading China -based biotechnology ... biopharmaceutical products, announced today that, at an extraordinary ... shareholders voted in favor of the proposal to ... plan of merger dated February 8, 2013, among ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... , Opposes use of imported drugs often ... Dec. 4 Today, the senior advocacy group RetireSafe urged the ... RetireSafe President Thair Phillips said, "Senator Dorgan,s importation amendment is poised ... be breached, and our health to be endangered. We could ...
... ... of the AcceleDent System , which is an acceleration device ... course published by PennWell Corporation , a leader in professional ... focuses on patient views about orthodontic treatment, a summary of treatment ...
Cached Medicine Technology:RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: